

Applicants : Daniel J. Capon, Jeannette M. Whitcomb and
Neil T. Parkin
Serial No. : CPA of 09/126,559
Filed : July 30, 1998
Page 2

target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and

(d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HCV drug,

wherein a test concentration of the anti-HCV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c) and a change in expression of the indicator gene in (c), as compared to (d), relates to susceptibility of HCV replication to the anti-HCV drug.

37. (Amended) A method for determining susceptibility of hepatitis C viral replication to an anti-hepatitis C virus (HCV) drug comprising:

- (a) introducing a resistance test vector comprising a patient-derived segment which comprises a hepatitis C virus (HCV) gene and a nonfunctional indicator gene into a host cell;
- (b) culturing the host cell from (a);
- (c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and
- (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HCV drug,

wherein a test concentration of the anti-HCV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c) and a change in expression of the indicator gene in

Applicants : Daniel J. Capon, Jeannette M. Whitcomb and
Neil T. Parkin
Serial No. : CPA of 09/126,559
Filed : July 30, 1998
Page 3

E2. (c), as compared to (d), relates to susceptibility of
HCV replication to the anti-HCV drug.

E3. 55. (Amended) A method for determining resistance of hepatitis
C virus (HCV) to an anti-HCV drug in a patient comprising:

- (a) developing a standard curve of drug susceptibility
for the anti-HCV drug;
- (b) determining susceptibility of HCV replication to
such anti-HCV drug in the patient according to the
method of claim 1; and
- (c) comparing the anti-HCV drug susceptibility from step
(b) with the standard curve from step (a), wherein
a decrease in susceptibility of HCV replication to
the anti-HCV drug indicates development of
resistance to the anti-HCV drug in the patient.

56. (Amended) A method for determining resistance of hepatitis
C virus (HCV) to an anti-HCV drug in a patient comprising:

- (a) developing a standard curve of drug susceptibility
for such anti-HCV drug;
- (b) determining susceptibility of HCV replication to
such anti-HCV drug in the patient according to the
method of claim 37; and
- (c) comparing the anti-HCV drug susceptibility from step
(b) with the standard curve from step (a), wherein
a decrease in susceptibility of HCV replication to
the anti-HCV drug indicates development of
resistance to the anti-HCV drug in the patient.

Applicants : Daniel J. Capon, Jeannette M. Whitcomb and
Neil T. Parkin
Serial No. : CPA of 09/126,559
Filed : July 30, 1998
Page 4

57. (Amended) A method for determining resistance of hepatitis C virus (HCV) to an anti-HCV drug in a patient comprising:

- Handwritten: F3*
- (a) determining susceptibility of hepatitis C viral replication in the patient to the anti-HCV drug at a first time according to the method of claim 1, wherein the patient-derived segment is obtained from the patient at about said time;
 - (b) determining susceptibility of hepatitis C viral replication of the same patient to the anti-HCV drug at a later time; and
 - (c) comparing the anti-HCV drug susceptibilities from steps (a) and (b), wherein a decrease in susceptibility of HCV replication to the anti-HCV drug at the later time as compared to the first time indicates development or progression of resistance to the anti-HCV drug in the patient.

58. (Amended) A method for determining resistance of hepatitis C virus (HCV) to an anti-HCV drug in a patient comprising:

- Handwritten: F3*
- (a) determining susceptibility of hepatitis C viral replication in the patient to the anti-HCV drug at a first time according to the method of claim 37, wherein the patient-derived segment is obtained from the patient at about said time;
 - (b) determining susceptibility of hepatitis C viral replication of the same patient to the anti-HCV drug at a later time; and
 - (c) comparing the anti-HCV drug susceptibilities from steps (a) and (b), wherein a decrease in susceptibility of HCV replication to the anti-HCV drug at the later time as compared to the first time indicates development or progression of resistance to the anti-HCV drug in the patient.